Please join the Association for Accessible Medicines (AAM) for a briefing to discuss the proposed NAFTA agreement, its impact on rising prescription drug prices and recommendations for a stronger agreement.
A lunch briefing hosted by the Association for Accessible Medicines (AAM) and its Biosimilars Council to learn more about the promise that biosimilars offer to patients and the health care system, and the challenges to the nascent market.
GRx+Biosims is the name of the combined event that replaces FallTech, Leading on Biosimilars and CMC Workshop. The program will be comprehensive and the speakers are the top in their field. Whatever your interests, you will find what you need at GRx+Biosims.
Join The Biosimilars Council and the Association for Accessible Medicines for cocktails and networking with other women in health policy. This nonpartisan event will be an opportunity to reconnect with old colleagues and meet new ones.
The Atlantic gathered key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States. How does the Food and Drug Administration implement the biosimilar approval pathway? Do biosimilar drugs require the same clinical trials as the biologics on which they are modeled? How will the process impact access and affordability, and what does it mean for innovation?
If the entire Affordable Care Act (#ACA) is overturned as unconstitutional, it could eliminate the Biologics Price Competition and Innovation Act (#BPCIA) and threaten the accessibility of life-saving treatments in the U.S.